Invitrogen Corp. agreed to pay $95 million in cash to purchase certain product lines and technology rights from PanVera LLC, a wholly owned subsidiary of Vertex Pharmaceuticals Inc. (BioWorld Today)
Invitrogen Corp. agreed to pay $95 million in cash to purchase certain product lines and technology rights from PanVera LLC, a wholly owned subsidiary of Vertex Pharmaceuticals Inc. (BioWorld Today)
Two weeks after a positive FDA advisory panel hearing, Genzyme General and partner BioMarin Pharmaceutical Inc. said Wednesday the agency issued a complete response letter for Aldurazyme without requesting additional clinical data for final approval. (BioWorld Today)
Two weeks after a positive FDA advisory panel hearing, Genzyme General and partner BioMarin Pharmaceutical Inc. said Wednesday the agency issued a complete response letter for Aldurazyme without requesting additional clinical data for final approval. (BioWorld Today)
